Pharmaceutical Therapies

Download an overview of this event for easy sharing » The COVID-19 pandemic sparked international concern about vulnerabilities in the global supply chain and disrupted the production of crucial pharmaceutical ingredients around the world. In a strained, but resilient market, two promising vaccine candidates boasting nearly 95% effectiveness rose to the top of various formulations. While […]

*This was a sponsored event. Speaker Jenny Bryant, MBA, serves as executive vice president of policy and research for the Pharmaceutical Research and Manufacturers of America (PhRMA). PhRMA advocates for public policies that encourage the discovery of life-saving and life-enhancing new medicines for patients by biopharmaceutical research companies. Ms. Bryant leads PhRMA’s policy and research […]

COVID-19 Webinar Series Overview This COVID-19 Webinar Series synthesizes the information in the headlines to provide cohesive insight into the status of the response and remaining gaps in the system that must be addressed to limit the severity of the COVID-19 outbreak in the United States. Session 15 – The Pharmaceutical Supply Chain The COVID-19 […]

We would like to invite you to join us for a day-long conference focusing on the fundamentals of health policy, the American health care system, and how it relates to the legislative process. “Health Policy Academy” is ideal for Congressional staff members looking to expand and strengthen their knowledge of health policy through panel discussions […]

Public Briefing Cell and gene therapies are a promising frontier in biomedical innovation that have the potential to cure deadly and debilitating diseases. Over the past two years, several breakthrough therapies that treat cancers and genetic diseases have been approved by the FDA. Today there are more than 300 cell and gene therapies in development. […]

Public Briefing The Medicare Part D program, an optional prescription drug benefit plan, currently covers over two-thirds of Medicare beneficiaries. The changing prescription drug landscape, including rising prices for prescriptions, has challenged the design of the program. This briefing oriented the audience to proposals introduced by Congress and the administration to reform Medicare Part D. […]

Public Briefing While pharmaceutical innovation has resulted in treatments—and in some cases, cures—for debilitating diseases, high prescription drug prices have precluded access for many people in the U.S. This fall, Congress and the administration are poised to consider many policies to reform the prescription drug market and reduce prices paid by consumers as well as […]

Public Webinar Health care has remained a leading issue in the 116th Congress and bipartisan momentum is growing around several key priorities. This fall, the House and Senate are poised to consider legislation surrounding drug pricing, surprise out-of-network billing, and various health care “extenders,” among other topics. With the 2020 presidential election cycle approaching, attention […]